Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.37 |
| ▸ | GSK3B | P49841 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19304186 | 0.76 | PTGS2 (0.37) | PTGS2GSK3BALDH1A1 | |
| SCHEMBL6693898 | 0.76 | PTGS2 (0.45) | PTGS2GSK3B | |
| SCHEMBL21419681 | 0.76 | GSK3B (0.36) | PTGS2GSK3B | |
| SCHEMBL8801436 | 0.75 | PTGS2 (0.36) | PTGS2GSK3BALDH1A1 | |
| SCHEMBL5124396 | 0.75 | GRK5 (0.42) | PTGS2GSK3BALDH1A1 | |
| SCHEMBL13883926 | 0.75 | PTGS2 (0.44) | PTGS2GSK3B | |
| SCHEMBL13524794 | 0.73 | KMT2A (0.35) | PTGS2 | |
| SCHEMBL24574575 | 0.72 | MMP1 (0.33) | PTGS2 | |
| SCHEMBL278635 | 0.72 | GSK3B (0.48) | PTGS2GSK3BALDH1A1 | |
| SCHEMBL8759244 | 0.70 | GSK3B (0.43) | PTGS2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583803-B1 | OXIDATION PROCESS FOR PREPARING HIGHLY DISPERSIBLE QUINACRIDONE PIGMENTS | BASF SE (DE) | 2010-07-28 | — | — | EP | disclosed |
| US-7161007-B2 | Oxidation process for preparing quinacridone pigments | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1521809-B1 | OXIDATION PROCESS FOR PREPARING QUINACRIDONE PIGMENTS | CIBA SC HOLDING AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176959-A1 | Oxidation process for preparing quinacridone pigments | CIBA SPECIALTY CHEMICALS CORP. | 2005-08-11 | — | — | US | disclosed |
| US-6867301-B2 | Oxidation process for highly dispersible quinacridone pigments | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2005-03-15 | — | — | US | disclosed |
| US-20040138458-A1 | Oxidation process for highly dispersible quinacridone pigments | CIBA SPECIALTY CHEMICALS CORP. | 2004-07-15 | — | — | US | disclosed |
| EP-0829523-B1 | Oxidation process for preparing quinacridone pigments | CIBA SC HOLDING AG (CH) | 2001-09-12 | — | — | EP | disclosed |
| EP-0894832-B1 | Process for the preparation of quinacridone solid solutions | CIBA SC HOLDING AG (CH) | 2001-08-08 | — | — | EP | disclosed |
| US-6013127-A | Process for the preparation of quinacridone solid solutions | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2000-01-11 | — | — | US | disclosed |
| EP-0894832-A2 | Process for the preparation of quinacridone solid solutions | Ciba SC Holding AG (CH) | 1999-02-03 | — | — | EP | disclosed |
| EP-0829523-A2 | Oxidation process for preparing quinacridone pigments | Ciba SC Holding AG (CH) | 1998-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176959-A1 | Oxidation process for preparing quinacridone pigments | SQOR, NDUFS6, NQO1 | PTGS2 1650/4885GSK3B 4107/4885ALDH1A1 86/4885 |
| US-20040138458-A1 | Oxidation process for highly dispersible quinacridone pigments | NDUFA6, NDUFS6, NDUFA3 | PTGS2 1718/4885GSK3B 3389/4885ALDH1A1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.